Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00392431|
Recruitment Status : Completed
First Posted : October 26, 2006
Last Update Posted : March 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Persistant Atrial Fibrillation||Drug: amiodarone||Not Applicable|
To determine differences in adverse event rates between patients with persistent atrial fibrillation who are randomized to episodic amiodarone treatment (EAT) strategy and patients who are randomized to continuous amiodarone treatment (CAT) strategy, while atrial fibrillation is still effectively suppressed.
Adverse events can be related to:
- amiodarone use
- atrial fibrillation itself or underlying heart disease.
To determine differences in quality of life between patients with persistent atrial fibrillation who are randomized to the EAT strategy and patients who are randomized to the CAT strategy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||220 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Continuous Versus Episodic Prophylactic Treatment With Oral Amiodarone for the Prevention of Permanent Atrial Fibrillation: a Randomized Study on Morbidity and Quality of Life|
|Study Start Date :||January 2003|
|Actual Study Completion Date :||March 2007|
- Adverse events related to amiodarone use and/or atrial fibrillation itself or underlying heart disease
- Quality of life
- Number of patients with permanent AF at the end of the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00392431
|University Medical Center Groningen|
|Groningen, Netherlands, 9700RB|
|Principal Investigator:||Isabelle C Van Gelder, MD||University Medical Center Groningen|